Kymera (KYMR) — Oral Protein Degradation in InflammationKymera Therapeutics, Inc.BATS:KYMRRichtv_officialKymera KYMR is a clinical-stage biotech advancing oral targeted protein degradation therapies across autoimmune disease, inflammation, and oncology—positioned as a leader in next-gen small-molecule immunology. Key Catalysts KT-621 (STAT6 degrader) = Flagship Program: A potential first-in-class oral STAT6 degrader, advancing through Phase 2b in atopic dermatitis and eosinophilic asthma—large markets where oral convenience and targeted mechanism can drive adoption. Next Wave Pipeline: KT-579 (IRF5 degrader) is entering Phase 1, with initial data expected 2H 2026, adding a meaningful catalyst and expanding Kymera’s footprint in inflammatory biology. Platform Validation + Funding Strength: Collaboration with Gilead Sciences provides external validation and non-dilutive support, strengthening balance-sheet flexibility and execution capacity. Why It Matters ✅ Oral degraders can offer biologic-like selectivity with pill convenience ✅ Multiple independent shots on goal across immunology targets ✅ Strong partner backing reduces financing pressure Investment Outlook Bullish above: $74–$75 Upside target: $110–$115, driven by KT-621 Phase 2b progress, KT-579 clinical entry, and platform validation.